NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Analysis

Arcturus Therapeutics Holdings Inc. (ARCT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ARCT

$15.82

+$0.26 (+1.67%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARCT with… →

ARCT Key Statistics

As of Sep 4, 2026
Trading
Open
$15.61
Previous Close
$15.56
Day's Range
15.40–16.02
52-Week Range
5.50–24.17
Volume
534.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.48
Valuation
Market Cap
$449.65M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
15.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.39
Financials (FY)
Revenue (FY)
$67.22M−51.43%
Net Income (FY)
−$65.78M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
28.42M
1-Year Return
−5.61%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
824.04K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARCT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+158.08%
2025−63.88%
2024−46.18%
2023+85.91%
2022−54.17%
2021−14.68%
2020+299.08%
2019+139.96%
2018−43.02%
2017−45.92%
2016 (partial year)−55.79%

As of September 4, 2026.

ARCT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$67.22M−$65.78M−97.9%
2024$138.39M−$80.94M−58.5%
2023$157.75M−$29.73M−18.8%
2022$205.76M$9.35M4.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$67.22M—−$76.26M−$65.78M−97.9%
2024$138.39M—−$95.67M−$80.94M−58.5%
2023$157.75M—−$78.21M−$29.73M−18.8%
2022$205.76M—$12.18M$9.35M4.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARCT Valuation vs Biotechnology Median

Median of 656 stocks
MetricARCTBiotechnology medianvs median
P/S ratio15.3115.260% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Arcturus Therapeutics Holdings Inc. (ARCT) carries a market capitalisation of $449.65M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 106.

ARCT last closed at $15.82 on September 4, 2026. That is +$0.26 (+1.67%) against the previous close. Over the past 52 weeks the price has ranged from $5.50 to $24.17. The latest close sits 187.64% above that 52-week low.

Financial Health

In fiscal 2025, Arcturus Therapeutics Holdings Inc. reported revenue of $67.22M. Against the prior fiscal year total of $138.39M, that is a change of −51.43%. The same year closed with a net loss of $65.78M. Profit margin runs at 0%. Trailing earnings per share are −3.39.

Across the 4 fiscal years on file, revenue moves from $205.76M in 2022 to $67.22M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 15.31. On price-to-sales that is 0.31% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 2.48. Annualized volatility over the trailing 10 years is 96.87%. The trailing one-year price return is −5.61%. Across 10 years the annualized return works out at −7.20%.

Growth & Income

No dividend is on file for ARCT.

So far in 2026 the price is +158.08%. The strongest complete calendar year on file is 2020 at +299.08%; the weakest is 2025 at −63.88%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Arcturus Therapeutics Holdings Inc. (ARCT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arcturus Therapeutics Holdings Inc. ARCT $449.65M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Arcturus Therapeutics Holdings Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Visit website →